相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Letter
Critical Care Medicine
Chris Ka Pun Mok et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
(2022)
Review
Immunology
Paul Moss
Summary: T cell immunity plays a central role in controlling SARS-CoV-2 infection, with early responses correlating with protection. T cell memory provides broad recognition of viral proteins, limiting the impact of viral variants and offering protection against severe disease. Current COVID-19 vaccines elicit robust T cell responses, contributing to the prevention of hospitalization or death. Therefore, the importance of T cell immunity may have been underestimated.
Article
Biochemistry & Molecular Biology
Samuel M. S. Cheng et al.
Summary: Specific antibody levels against the SARS-CoV-2 Omicron variant decrease significantly after two doses of BNT162b2 or CoronaVac vaccines, but can be markedly increased with a booster dose of BNT162b2. Individuals who previously received two doses of BNT162b2 or CoronaVac showed reduced serum antibody titers against Omicron, while a BNT162b2 booster dose increased the antibody levels in the majority of individuals. This suggests mRNA vaccine boosters may be necessary in countries primarily using CoronaVac vaccines to combat the spread of Omicron.
Article
Biochemistry & Molecular Biology
Eddy Perez-Then et al.
Summary: The study found that a BNT162b2 mRNA vaccine booster can enhance neutralizing antibodies against the Omicron variant in individuals who received two doses of the CoronaVac vaccine, but antibody titers remain lower compared to the ancestral virus and the Delta variant.
Article
Respiratory System
Chris Ka Pun Mok et al.
Summary: The study found that vaccination with BNT162b2 induces significantly stronger humoral immune responses than CoronaVac. Additionally, BNT162b2 vaccine recipients had higher levels of antibody protection threshold. Age was negatively correlated with antibody levels post-vaccination. Both vaccines induced SARS-CoV-2-specific T-cell responses, but CoronaVac elicited higher levels of structural protein-specific T-cell responses.
Article
Immunology
Harika Oyku Dinc et al.
Summary: Healthcare workers were among the first groups to be vaccinated in Turkey, and two doses of CoronaVac vaccine produced effective humoral immunity in HCWs. The antibody response was significantly higher in those with a prior history of COVID-19, suggesting that a single shot of vaccination may be sufficient for this group.
Article
Medicine, General & Internal
Ruediger Gross et al.
Summary: According to a study on a cohort of individuals who received heterologous ChAdOx1 nCoV-19 BNT162b2 vaccination, the regimen induced potent humoral and cellular immune responses, with strong neutralization of the most prevalent SARS-CoV-2 variants. The results suggest that this heterologous vaccination regimen is at least as immunogenic and protective as homologous vaccinations and also offers protection against current variants of concern.
Article
Multidisciplinary Sciences
Fanglei Zuo et al.
Summary: This study demonstrates that an mRNA vaccine booster in individuals vaccinated with inactivated vaccines can significantly increase the humoral and cellular immune responses against the virus, including the Omicron variant.
NATURE COMMUNICATIONS
(2022)
Article
Microbiology
Ferda Ozyurda et al.
Summary: This study investigated the humoral and cellular immunity levels of hospital employees in Turkey who received the CoronaVac and Comirnaty vaccines. It found that the heterogeneous vaccine group had higher levels of immunity compared to those who received three doses of the same vaccine. Additionally, more side effects were reported in individuals who received the Comirnaty vaccine. The study suggests that heterologous vaccination should be preferred in vaccination strategies.
MIKROBIYOLOJI BULTENI
(2022)
Article
Immunology
Florencia Rammauro et al.
Summary: Heterologous prime-boost vaccination with CoronaVac and BNT162b2 led to a significant increase in serum anti-RBD specific antibody levels followed by a decrease. However, these levels remained higher than those in individuals vaccinated only with CoronaVac. Serum IgG levels were correlated with antibody binding, blocking RBD-ACE2 interaction, and Fc-effector mechanisms. This study provides insights into the humoral immune response to heterologous vaccination and the scheduling of future vaccine boosters.
Article
Multidisciplinary Sciences
Katherine McMahan et al.
Summary: Adoptive transfer of purified IgG from convalescent macaques protects naive macaques against SARS-CoV-2 infection, and cellular immune responses contribute to protection against rechallenge with SARS-CoV-2. The findings suggest that relatively low antibody titres are sufficient for protection against SARS-CoV-2 in macaques, while higher antibody titres are required for treatment of SARS-CoV-2 infection.
Letter
Medicine, General & Internal
Alicia T. Widge et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Microbiology
Sebnem Senol Akar et al.
Summary: This study evaluated the efficacy and side effects of the CoronaVac® vaccine in healthcare workers, finding that 25% had sufficient antibody response 28 days after the first dose and 97% after the second dose, with stronger responses in younger ages, females, non-smokers, and those previously exposed to SARS-CoV-2. Further research is needed to confirm the vaccine's effectiveness in real-life settings.
MIKROBIYOLOJI BULTENI
(2021)
Article
Oncology
Yifei Ma et al.
Summary: This study investigated the impact of PD-1B on vaccination outcomes in patients receiving cancer treatment. Results showed that seroconversion was not affected in patients receiving PD-1B after COVID-19 vaccination. A nomogram predicting the risk of seroconversion failure was developed, with variables including age, pathology, and chemotherapy status.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Letter
Medicine, General & Internal
Nicole Doria-Rose et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Virology
Aysen Bayram et al.
Summary: The study conducted antibody quantitation of the SARS-CoV-2 spike protein in healthcare workers in a university hospital in Turkey who were vaccinated with two doses of CoronaVac. It found a relatively high frequency of humoral immunity in HCWs aged 18-59 after vaccination. Antibody levels were significantly higher in individuals who had COVID-19 before vaccination and significantly lower in those with chronic diseases, suggesting the importance of monitoring antibody response for vaccine dosage decisions, especially in vulnerable groups.
JOURNAL OF MEDICAL VIROLOGY
(2021)
Article
Immunology
Jialu Zhang et al.
Summary: The study found significant differences in humoral and cellular immune responses induced by different vaccine platforms when administered individually in a mouse model. Boosting with recombinant subunit, adenovirus vectored or mRNA vaccine after two doses of inactivated vaccine improved immune responses compared to a third dose of inactivated vaccine. This provides new ideas for prophylactic vaccination strategy against SARS-CoV-2.
EMERGING MICROBES & INFECTIONS
(2021)
Review
Public, Environmental & Occupational Health
Amy Vassallo et al.
Summary: The global call for sex/gender-disaggregated data in COVID-19 research has led to important findings about the disease's impacts, including on testing, incidence, severity, hospitalizations, and deaths. This review of COVID-19 vaccine research found that while clinical trials had equal representation of women and men, observational studies had a higher percentage of women. However, there was a lack of reporting and analysis of vaccine efficacy and safety data by sex/gender, with a majority of adverse events being reported by women.
FRONTIERS IN GLOBAL WOMENS HEALTH
(2021)
Article
Immunology
Tatjana Schwarz et al.
Summary: After receiving the BNT162b2 vaccine, elderly individuals in Germany showed delayed and reduced antibody and T-cell responses compared to healthcare workers, indicating the potential need for additional immunizations for this age group. Nonpharmaceutical interventions for coronavirus disease remain crucial based on this data.
EMERGING INFECTIOUS DISEASES
(2021)
Article
Immunology
Wanbo Tai et al.
CELLULAR & MOLECULAR IMMUNOLOGY
(2020)
Review
Immunology
Nicolas Vabret et al.
Article
Multidisciplinary Sciences
Takehiro Takahashi et al.
Article
Immunology
Yanchun Peng et al.
Review
Immunology
Nirupa Gadi et al.
FRONTIERS IN IMMUNOLOGY
(2020)
Review
Immunology
Mangalakumari Jeyanathan et al.
NATURE REVIEWS IMMUNOLOGY
(2020)
Review
Immunology
Stylianos Bournazos et al.
INTERNATIONAL IMMUNOLOGY
(2017)
Review
Immunology
Falk Nimmerjahn et al.
NATURE REVIEWS IMMUNOLOGY
(2008)
